New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:03 EDTBLUEBluebird Bio announces first patient transplanted in Phase 1/2 Northstar study
bluebird bio announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study -- HGB-204 -- in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. The phase 1/2 study is designed to evaluate the feasibility, safety and efficacy of LentiGlobin drug product in the treatment of subjects with beta-thalassemia major. The study is designed to enroll up to fifteen subjects. Subjects will be evaluated for safety and efficacy post-transplant.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:03 EDTBLUECelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 29, 2015
18:09 EDTBLUEJuno surges after Celgene collaboration, CAR-T peers follow
Subscribe for More Information
June 24, 2015
09:07 EDTBLUECAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:06 EDTBLUEbluebird bio 2.94M share Spot Secondary priced at $170.00
Subscribe for More Information
June 23, 2015
16:01 EDTBLUEbluebird bio files to sell $400M in common stock
Subscribe for More Information
June 22, 2015
08:03 EDTBLUEKite Pharma, bluebird bio announce strategic collaboration
Subscribe for More Information
June 19, 2015
13:38 EDTBLUEOptions with decreasing implied volatility
Options with decreasing implied volatility: QIHU PIR RHT BLUE KMX RAD KBH ADBE ACM KR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use